Seong J. Seo

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 169 publications

Development of Metal-Enhanced Fluorescence Nanorods on Micro Post Arrays for Portable Detection of Human Semen Biomarkers.

Development of Metal-Enhanced Fluorescence Nanorods on Micro Post Arrays for Portable Detection of Human Semen Biomarkers.

Journal: Micromachines
Published: November 10, 2025

Efficacy and safety of autologous adipose-derived stem cells in subjects with moderate to severe atopic dermatitis: a multicenter, randomized, single-blind, placebo-controlled, phase 2 trial.

Efficacy and safety of autologous adipose-derived stem cells in subjects with moderate to severe atopic dermatitis: a multicenter, randomized, single-blind, placebo-controlled, phase 2 trial.

Journal: Stem cell research & therapy
Published: May 30, 2025

Effect of Particulate Matter in Atopic Dermatitis through HDACs and Filaggrin Alteration.

Effect of Particulate Matter in Atopic Dermatitis through HDACs and Filaggrin Alteration.

Journal: Journal of microbiology and biotechnology
Published: February 25, 2025

A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study with Post-hoc biomarker analysis.

A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study with Post-hoc biomarker analysis.

Journal: Frontiers in immunology
Published: February 13, 2025

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.

Journal: The Journal of dermatology
Published: February 08, 2025

Adipose-derived stem cell exosomes for treatment of dupilumab-related facial redness in patients with atopic dermatitis.

Adipose-derived stem cell exosomes for treatment of dupilumab-related facial redness in patients with atopic dermatitis.

Journal: The Journal of dermatological treatment
Published: June 05, 2023

Adipose tissue-derived exosomes alleviate particulate matter-induced inflammatory response and skin barrier damage in atopic dermatitis-like triple-cell model.

Adipose tissue-derived exosomes alleviate particulate matter-induced inflammatory response and skin barrier damage in atopic dermatitis-like triple-cell model.

Journal: PloS one
Published: January 19, 2023

Roles of Virtual Memory T Cells in Diseases.

Roles of Virtual Memory T Cells in Diseases.

Journal: Immune network
Published: January 18, 2023

Treatment of facial pigmented disorders with a 785-nm picosecond Ti:sapphire laser in Asians: A report of three cases.

Treatment of facial pigmented disorders with a 785-nm picosecond Ti:sapphire laser in Asians: A report of three cases.

Journal: Dermatologic therapy
Published: August 08, 2022

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.

Journal: American journal of clinical dermatology
Published: March 10, 2022

Evaluation of the efficacy and safety of the 1064 nm picosecond Nd:YAG laser with a topically applied gold and diamond suspension for facial skin rejuvenation: A pilot study.

Evaluation of the efficacy and safety of the 1064 nm picosecond Nd:YAG laser with a topically applied gold and diamond suspension for facial skin rejuvenation: A pilot study.

Journal: Dermatologic therapy
Published: February 22, 2022

Symmetric drug-related intertriginous and flexural exanthema-like eruption related to coronavirus disease 2019 vaccine.

Symmetric drug-related intertriginous and flexural exanthema-like eruption related to coronavirus disease 2019 vaccine.

Journal: Contact dermatitis
Published: February 14, 2022
Showing 1-12 of 169

Last Updated: 09/26/2026